Form 8-K NEKTAR THERAPEUTICS For: Sep 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Nektar Therapeutics (NKTR) Sees Early Weakness
September 27, 2016 9:50 AM EDTNektar Therapeutics (NASDAQ: NKTR) is under heavy pressure this morning. Shares are down 8.6% on volume that is running 49x normal.
This morning, Bristol-Myers Squibb Company (NYSE: BMY) and Nektar Therapeutics... More
Nektar Therapeutics (NKTR) Offers Additional Detail on Bristol-Myers Squibb Collaboration
September 27, 2016 7:50 AM EDTNektar Therapeutics (Nasdaq: NKTR) disclosed the following in a U.S. SEC filing on Tuesday:
Item 1.01 Entry into a Material Definitive Agreement.
On September 21, 2016, Nektar Therapeutics, a Delaware corporation (Nektar), entered into a Clinical Trial Collaboration Agreement (the Agreement) with Bristol-Myers Squibb Company, a Delaware corporation (BMS), pursuant to which Nektar and BMS will collaborate to conduct Phase 1/2 clinical trials evaluating Nektars IL-2-based CD122-biased agonist, known as NKTR-214, and BMSs human monoclonal antibody that binds PD-1, known as Nivolumab, as a potential combination treatment regimen in five tumor types... More
